160 results
6-K
EX-99.1
BLRX
Bioline Rx Ltd
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry
6-K
EX-99
BLRX
Bioline Rx Ltd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
of APHEXDA; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies
6-K
EX-99.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
additional financing, including any unexpected costs or delays in the ongoing commercialization of APHEXDA;
risks related to changes in healthcare laws … , including any unexpected costs or delays in the ongoing commercial launch of APHEXDA;
risks related to changes in healthcare laws, rules
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
, including any unexpected costs or delays in the ongoing commercialization of APHEXDA;
risks related to changes in healthcare laws, rules … -party payor reimbursement practices or healthcare reform initiatives, any of which could harm our business.
We rely upon third-party manufacturers
6-K
EX-99
qlgs2m5
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
7kmrutuke
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
vzrc8g083azn ubr0bo
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
cjlos7v
16 Feb 24
Current report (foreign)
7:07am
F-3
hhescu6ygbzvlyt199
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
u66sx2un
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
rvkhw2o9qh3 tiu
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
nc5z4ep
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
gx3k fcxkfd
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
yelbfk1
28 Sep 23
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
7:11am
6-K
EX-99
xyo 9fzbdkbw
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
4lzrwi
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
4aiocm
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-1
kdvjsacq8rvc2p1z1qsn
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am